Monthly prices for recently-approved oncology drugs in the US and Europe show little correlation with value assessments by leading medical professional societies, according to a study by Kerstin Vokinger, University of Zurich, et al., in the May issue of The Lancet Oncology.
The study compares US and European prices for 46 drugs for solid tumors with benefit assessments using the American Society of Clinical Oncology value framework and the European Society for Medical Oncology Magnitude of Clinical Benefit Scale
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?